Compare VEEV & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEV | DVAX |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5B | 1.3B |
| IPO Year | 2013 | 2004 |
| Metric | VEEV | DVAX |
|---|---|---|
| Price | $224.43 | $15.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 27 | 5 |
| Target Price | ★ $299.92 | $26.50 |
| AVG Volume (30 Days) | 1.7M | ★ 3.0M |
| Earning Date | 11-20-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.69 | N/A |
| EPS | ★ 5.13 | N/A |
| Revenue | ★ $3,080,246,000.00 | $330,514,000.00 |
| Revenue This Year | $17.74 | $24.63 |
| Revenue Next Year | $12.24 | $15.85 |
| P/E Ratio | $43.50 | ★ N/A |
| Revenue Growth | 15.96 | ★ 26.73 |
| 52 Week Low | $201.54 | $9.20 |
| 52 Week High | $310.50 | $15.49 |
| Indicator | VEEV | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.92 | 89.00 |
| Support Level | $221.42 | $10.78 |
| Resistance Level | $225.78 | $15.49 |
| Average True Range (ATR) | 5.47 | 0.22 |
| MACD | 1.74 | 0.44 |
| Stochastic Oscillator | 38.22 | 97.74 |
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.